Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 8-K (Current Report)
Date of Report: May 22, 2025
Reporting Period: Events occurring on May 22, 2025, regarding the termination of agreements entered into in April 2025.
Key Financial Metrics
This filing does not contain standard financial statements (revenue, profit, cash flow, or margins). The financial impact is limited to the reversal of previously announced equity issuances and the retention of a specific share block:
- Equity Issuance Reversal: 1,600,000 shares (Smokeless) and 120,000 shares (Strategem) were cancelled or waived.
- Equity Retention: 50,000 shares retained by ArcStone Securities as consideration for services rendered.
- Valuation Reference: ArcStone shares were previously valued at $2.57 per share ($257,000 total for 100,000 shares).
- Debt/Liquidity: No new debt incurred; no cash payments made for the terminated agreements.
Material Changes Versus Prior Period
The Company reversed three material definitive agreements announced in April 2025:
- ArcStone Securities: Terminated a six-month consulting agreement. Of the 100,000 shares issued, 50,000 were cancelled, and 50,000 were retained by ArcStone.
- Smokeless Technology Corp: Terminated an Intellectual Property Purchase Agreement regarding oral pouch technology. The Company returned all purchased IP, and Smokeless cancelled all 1,600,000 shares previously issued.
- Strategem Solutions Inc: Terminated a consulting agreement for a smokeless product vertical. Strategem waived the issuance of 120,000 shares (which had not yet been issued) and the Company incurred no cash payment obligations.
Guidance, Outlook, and Risks
Management Commentary: The Company executed Mutual Rescission and Release Agreements with all three parties. No material early termination penalties were incurred other than the retention of the 50,000 ArcStone shares.
Risks and Contingencies: The filing notes that the summary is qualified by the full text of the Rescission Agreements (Exhibits 10.1, 10.2, and 10.3), which contain continuing representations and warranties. The Company has effectively exited the planned expansion into the smokeless oral pouch market via the Smokeless acquisition.
Investor Verification Checklist
- Verify the cancellation of 1,600,000 Smokeless shares and 120,000 Strategem shares in the Company's cap table.
- Confirm the outstanding status of the 50,000 ArcStone shares retained as compensation.
- Review Exhibits 10.1, 10.2, and 10.3 for any continuing liabilities or representations not fully released.
- Assess the strategic impact of abandoning the smokeless product vertical and the associated IP.